

23 June 2008

Lifeline Scientific, Inc
("Lifeline" or "the Company")

Results of AGM

Lifeline Scientific, the medical technology company, announces that at its annual general meeting held on 20 June 2008, the resolution was duly passed to reelect Mr. Eric Swenden to the Company's Board of Directors for a three year term.

Enquiries

Lifeline Scientific, Inc.	
David Kravitz, CEO	
Seymour Pierce (Nomad)	+44 (0)20 7107 8000
Mark Percy / Huaizheng Peng / Sarah Jacobs	
Financial Dynamics	+44 (0)20 7831 3113
Ben Brewerton / John Dineen	

Notes to Editors

The LifePort Kidney Transporter is the Group's lead product. It is designed with the challenges of organ recovery and transport in mind, and provides a sealed, sterile, protected environment where a physiologic chemical solution is gently pumped through the donated kidney at cold temperatures to minimise tissue damage while the organ is outside the body.

Since receiving FDA clearance and CE Marking in 2004, over 250 LifePorts have been employed in pilot programs with leading transplant organizations throughout Europe and North America, preserving more than 12,000 kidneys for clinical transplantation.

Initial clinical outcomes studies have shown that machine preservation improves the quality of a kidney from a cadaveric donor prior to transplantation in comparison to organs statically stored in a traditional cool box. This data demonstrates that machine perfused kidneys are more likely to function immediately after transplantation, remain healthier for longer. Results from an independent investigator driven multi-national, prospective, randomized clinical trial employing LifePort are expected to be published later this year.